Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.
Chemomab Therapeutics Ltd. reports developments for its clinical-stage biotechnology program in fibro-inflammatory diseases. Recurring updates center on nebokitug, an antibody targeting CCL24, and its clinical evaluation in primary sclerosing cholangitis through the SPRING trial, related open-label extension data, biomarker findings, macrophage-mediated mechanism research, and peer-reviewed or medical-meeting presentations.
Company news also covers financial results, corporate updates, regulatory interactions with agencies, preparations for later-stage development, strategic partnering discussions, capital-raising activity involving American Depositary Shares, and participation in healthcare and rare-disease investor conferences.
Chemomab Therapeutics (Nasdaq: CMMB) announced that CEO Dr. Adi Mor will deliver a prerecorded corporate presentation at the H.C. Wainwright 28th Annual Global Investment Conference. The webcast will be available starting September 11, 2026 at 7:00 am ET for 90 days via an online link and the Events section of the Chemomab website.
Dr. Mor and Scipher Medicine CEO Dr. Reg Seeto will attend the conference in New York to co-host 1x1 investor meetings on September 14‑16, 2026. Chemomab and Scipher signed a definitive merger agreement on July 8, 2026, with closing expected before year-end, and Scipher plans to advance Chemomab’s anti-CCL24 antibody nebokitug into a Phase 2 rheumatoid arthritis trial.
Chemomab Therapeutics (Nasdaq:CMMB) reported second quarter 2026 results and progress on its proposed all-stock merger with Scipher Medicine. Under the merger agreement, Chemomab holders are expected to own about 32% of a combined company valued at $150 million, before a concurrent $30 million private placement with 100% warrant coverage.
The combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, into a Phase 2 rheumatoid arthritis trial starting in H1 2027, with topline data expected in H1 2028 and an anticipated cash runway through that readout. Q2 2026 R&D and G&A expenses were each $1.1 million, net loss was $2.2 million, and cash, cash equivalents and short-term deposits totaled $6.7 million, which Chemomab expects to fund operations through Q1 2027. Chemomab shareholders are also slated to receive CVRs tied to up to $50 million in future milestones related to nebokitug and the PSC program.
Chemomab Therapeutics (Nasdaq:CMMB) and Scipher Medicine agreed to a stock-based merger to form Scipher Medicine Corporation, expected to trade as “SCIP”. The combined company will prioritize advancing nebokitug, an anti-CCL24 antibody, into an AI-guided Phase 2 rheumatoid arthritis trial.
The merged company is valued at $150 million before a concurrent $30 million private placement from leading investors and expects cash runway into H2 2028, with a Phase 2 RA topline readout anticipated in H1 2028. Additional revenue comes from Scipher’s precision medicine, data and biopharma partnership businesses, including PrismRA®, a CMS-approved RA treatment response test.
Chemomab Therapeutics (Nasdaq:CMMB) reported Q1 2026 results and new nebokitug data in primary sclerosing cholangitis (PSC).
Proteomic and gene-expression analyses from the Phase 2 SPRING trial showed dose-dependent, statistically significant reductions in multiple fibrotic and inflammatory pathways, including in PSC patients with co-existing IBD. Cash was $8.0 million, with runway expected through Q1 2027; Q1 net loss was $1.8 million versus $3.3 million a year earlier, with R&D expenses reduced to $0.9 million from $2.5 million.
Chemomab (NASDAQ: CMMB) reported 2025 year-end results and a corporate update highlighting a successful FDA End-of-Phase 2 meeting for nebokitug and alignment on a single pivotal Phase 3 pathway in primary sclerosing cholangitis (PSC).
Key operational highlights include multiple scientific presentations, issued patents, senior clinical appointments, and publication of Phase 2 SPRING data. Financials: cash of $10.4M (12/31/2025) with a stated runway to end of Q1 2027, full-year R&D of $5.8M, G&A of $3.7M, and a 2025 net loss of $9.0M.
Chemomab Therapeutics (Nasdaq: CMMB) said CEO Dr. Adi Mor and senior management will present at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 at 8:00 am ET.
The corporate presentation will be webcast live and available on the company's investor relations website for 90 days; management will also hold one-on-one investor meetings.
Chemomab (Nasdaq: CMMB) announced publication (Nov 19, 2025) of Phase 2 SPRING results for nebokitug in primary sclerosing cholangitis (PSC) in the American Journal of Gastroenterology. The double-blind randomized study (n=76) evaluated IV nebokitug 10 mg/kg and 20 mg/kg vs placebo up to 15 weeks with an open-label extension to 48 weeks.
Key findings: nebokitug was generally safe and well tolerated through 48 weeks; dose-dependent biomarker improvements were observed, with the 20 mg/kg arm and patients with moderate/advanced fibrosis showing numerical and durable reductions in ELF, PRO-C3, and statistically significant reductions in liver stiffness at 15 weeks. Results support advancement to a Phase 3 registration trial.
Chemomab (Nasdaq: CMMB) announced that co-founder and CEO Adi Mor, PhD will present at Oppenheimer’s Movers in Rare Disease Summit on December 11, 2025 in New York City.
The company will deliver a corporate overview at 2:15–2:45 pm EST at the Sofitel Hotel and will be available for one‑on‑one investor meetings with registered attendees. Investors should contact their Oppenheimer representative to register and schedule meetings.
Chemomab (Nasdaq: CMMB) reported Q3 2025 results and a corporate update on Nov 20, 2025. Management said FDA and EMA provided alignment that a single nebokitug Phase 3 registration trial using a composite clinical event endpoint could support approval, and Phase 3 design is near completion.
Data from the Phase 2 SPRING open-label extension up to 48 weeks showed favorable safety and consistent improvements in inflammatory and fibrotic biomarkers. Cash, cash equivalents and short-term deposits were $10.2M as of Sept 30, 2025, funding operations through end of Q4 2026.
Chemomab (Nasdaq: CMMB) announced that new clinical data from the Phase 2 SPRING trial of nebokitug in primary sclerosing cholangitis (PSC) will be presented at AASLD The Liver Meeting® on November 10, 2025. Open-label extension (up to 48 weeks) data show nebokitug was well tolerated with sustained or continued improvements in inflammatory and fibrosis biomarkers, including ELF score and liver stiffness, especially at 20 mg/kg. Mechanistic analyses report dose-dependent reductions in macrophage-related proteins, a dose-dependent increase in MST1, and correlations between MST1/CCL24 changes and liver stiffness. All three posters were designated Posters of Distinction.